Focus topics


Feature
•

Will the Biontech approval gain new momentum?

Child vaccination with BioNTech in Hong Kong: a blueprint for the Mainland?
There is a mysterious gap in China’s Covid strategy: While other countries have stripped the disease of its terror through mRNA vaccination, China clings to expensive and excruciating lockdowns as its only remedy for Omicron. But now the approval of BioNTech’s vaccine could gain momentum.
By
Finn Mayer-Kuckuk
Image of Finn Mayer-Kuckuk

Shanghai continues to struggle under curfews, while Beijing begins to slip into a lockdown. The situation is so tense that the Communist Party’s highest asset is at risk: the general acceptance of its policies among the population. So it is baffling that public health policymakers are not grasping at every straw to alleviate the situation. To be specific, not a single mRNA vaccine is being administered in China. And the country’s own conventional vaccines have been injected in large numbers, but they are not particularly good at stopping Omicron (China.Table reported).

Continue reading now

Get 30 days of free access to the Decision Brief to read these and more quality news every day.

Try it for free

Are you already a guest at the China.Table? Log in now

Related

    Leading the world with key laboratories
    The US courts China – while the EU pouts
    Hong Kong on the anniversary: Beijing-red instead of democracy
    Zero-Covid: Criminals exploit Hong Kong’s isolation
Be our guest at the China.Table. Try it for free now, no automatic renewal.
Try it for free